Our results indicate that leytragin is a promising therapeutic agent for the prevention of cytokine storm with COVID-19 #Leutragin #leytragin
https://www.hindawi.com/journals/jir/2021/4414544/
5. Conclusions
In this study, we provide evidence that #leytragin, the peptide agonist of DOR, prevents the TLR4-mediated release of HMGB1 in the lungs.
Given the role of the TLR4/HMGB1 axis in the progression of pulmonary inflammation—including with cytokine storms occurring with COVID-19—our results indicate that leytragin is a promising therapeutic agent for the prevention of cytokine storm with COVID-19.
In a broader context, the opioidergic system in the lungs may present a promising target for the treatment of cytokine storms occurring with inflammatory lung diseases.
+
Prophylactic and Therapeutic Administration of #Leutragin Increases the Survival Rate of Animals in a Model of Fatal Acute Respiratory Distress Syndrome
+
New Russian drug – hope for unvaccinated people with COVID-19-related pneumonia
https://de.rt.com/russland/125336-interview-russisches-leutragin-wirksam-gegen/
There are three types of severity of a COVID-19 disease: mild, moderate and severe. What form is treated with Leutragin?
– It is only approved for patients with moderate illness. However, doctors have also used the drug in severe cases – they have taken responsibility for its use. Most importantly, there were no deaths after using the drug – and no patients whose condition got worse.
– For which age groups is the drug intended? Are there any restrictions on using it?
– It is approved for everyone, except children and pregnant women, and has the highest safety profile. The drug is intended for its own group: both men and women over the age of 18.
No comments:
Post a Comment